First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials.

ABSTRACT:

Introduction

Metastatic colorectal cancer (mCRC) is one of the most common cancers and the second leading cause of cancer worldwide. With the improvement of systemic and operative therapies, median overall survival (mOS) reached 30 months or longer. Here, we will review the use of the anti-vascular endothelial growth factor (VEGF) and anti-epidermal growth factor receptor (EGFR) antibodies in combination with doublet and triplet chemotherapy in patients with borderline and primary unresectable mCRC.

Methods

Phases II and III trials were included in investigating chemotherapy in the first-line in combination with an anti-VEGF(R) or anti-EGFR in a cohort of patients with mCRC.

Results

The VEGF-antibody bevacizumab has improved progression-free survival (PFS) in several

SUBMITTER: Vogel A 

PROVIDER: S-EPMC6604573 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature